Plain-English translation of NCT06128148 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage trial (Phase 1) testing a new drug called JYP0322 in patients with advanced cancers that have a specific genetic change called a ROS1 fusion. The medication is taken by mouth as a pill. The study will primarily focus on whether the treatment is safe and tolerable, and will also look at how your body processes it and whether it helps shrink or control your cancer.
Many cancers have specific genetic changes that can be targeted with precision medicines. This medication is designed to block the effects of the ROS1 genetic fusion, which occurs in some lung cancers, brain tumors, and other solid tumors. This trial will determine the right dose and confirm that the treatment is safe enough to test further in larger groups of patients.
You likely qualify if…
You likely don't qualify if…
You would take the medication by mouth once or twice daily, depending on which dose group you're assigned to. The study involves several visits where researchers will check your health, run blood tests, take imaging scans to see if your cancer is responding, and monitor you for any side effects. The exact length isn't specified here, but Phase 1 trials typically last several months to a year as they gradually test different dose levels to find the safest and most effective amount.
AI-generated summary from trial data · Aug 2, 2026 · Not medical advice
China